Company intelligence / Profile preview

Luxna Biotech Co., Ltd.

Ownership: Private
Employees: ~23
Development stage: Preclinical

Overview

The company has developed modified bridged oligonucleotides with high affinity for targeted mRNA and reduced risk of hepatotoxicity. They have a patent granted in January 2024 for a small cell lung cancer therapeutic agent containing oligonucleotide.

Therapeutic areas: OncologyNeurology
Modalities: Oligonucleotide therapeuticsAntisense oligonucleotides (ASO)
Industry: Biotech

Drug pipeline

1 asset

2'-O,4'-C-Spirocyclopropylene Bridged Nucleic Acid

Unknown

Partnerships

Servier (neurological diseases)Takeda (exclusive license for nucleic acid-based therapies)Aligos Therapeutics (targeting respiratory viruses including Coronaviridae)

Beyond the preview

Go deeper on Luxna Biotech Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Luxna Biotech Co., Ltd..

Explore the full profile